Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the breast cancer family registry

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 10, 2009, Pages 2723-2725

  Yazici, Hulya ^a   Terry, Mary Beth ^a   Yoon, Hee Cho ^a   Senie, Ruby T ^a   Liao, Yuyan ^a   Andrulis, Irene ^b,c,d   Santella, Regina M ^a  

^a Columbia University ^*  (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANCER CARE ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER REGISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MARKER GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; REGULATOR GENE;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 70350118568     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1237     Document Type: Article

References (21)

1. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-5482
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-692
3. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2002;25:315-319 (Pubitemid 30437320)
4. Agathanggelou A, Cooper WN, Latif F, Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-3508 (Pubitemid 40616319)
5. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699 (Pubitemid 32492810)
6. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-3109 (Pubitemid 32691961)
7. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20:1509-1518 (Pubitemid 32291201)
8. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-612 (Pubitemid 34160338)
9. Yeo W, Wong WL, Wong N, Law BK, Tse GM, Zhong S. High frequency of promoter hypermethylation of RASSF1A in tumorous and nontumourous tissue of breast cancer. Pathology 2005;37:125-130 (Pubitemid 40593403)
10. Dammann R, Schagdarsurengin U, Seidel C, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005;20:645-663 (Pubitemid 40468282)
11. Dulaimi E, Hillinck J, Ibanezd CI, Al Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189-6193 (Pubitemid 39287525)
12. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116
13. Müller HM, Widschwendter A, Fiegl H, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003;63:7641-7645 (Pubitemid 37466689)
14. Papadopoulou E, Davilas E, Sotiriou V, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci 2006;1075:235-243 (Pubitemid 44532790)
15. Hu XC, Wong IH, Chow LW. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol Rep 2003;10:1811-1815
16. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251-3256 (Pubitemid 29316030)
17. Hoque MO, Feng Q, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006;24:4262-4269 (Pubitemid 46630783)
18. Skvortsova TE, Rykova EY, Tamkovich SN, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 2006;94: 1492-1495
19. Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007;13:2378-2384 (Pubitemid 46698587)
20. Müller HM, Ivarsson L, Schröcksnadel H, et al. DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem 2004;50:1065-1068 (Pubitemid 38725799)
21. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344